Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of IMCgp100 in Patients with Advanced Melanoma
2016-002236-32Phase 2Terminated
- Sponsor
- Immunocore
- Start
- Oct 2016
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tebentafusp in melanoma, sponsored by Immunocore. Primary endpoint: Incidence of adverse events associated with IMCgp100. Started Oct 2016; status: terminated.
02
Drugs
tebentafusp
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-002236-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002236-32.